Separation and characterization of aggregated species of amyloid-beta peptides

Wiberg, Henning; Ek, Patrik; Pettersson, Frida Ekholm; Lannfelt, Lars; Emmer, Åsa; Roeraade, Johan
July 2010
Analytical & Bioanalytical Chemistry;Jul2010, Vol. 397 Issue 6, p2357
Academic Journal
We have investigated the use of isoelectric focusing and immunodetection for the separation of low molecular weight species of amyloid-beta (Aβ) peptides from their aggregates. From solutions of Aβ1–40 or Aβ1–42 monomeric peptides, low molecular weight material appeared at a p I value of ca. 5, while the presence of aggregates was detected as bands, observed at a p I of 6–6.5. The formation of Aβ aggregates (protofibrils) was verified by a sandwich ELISA, employing the protofibril conformation-selective antibody mAb158. In order to study the aggregation behavior when using a mixture of the monomers, we utilized the IEF separation combined with Western blot using two polyclonal antisera, selective for Aβ1–40 and Aβ1–42, respectively. We conclude that both monomers were incorporated in the aggregates. In a further study of the mixed aggregates, we used the protofibril conformation-selective antibody mAb158 for immunoprecipitation, followed by nanoelectrospray mass spectrometry (IP-MS). This showed that the Aβ1–42 peptide is incorporated in the aggregate in a significantly larger proportion than its relative presence in the original monomer composition. IP-MS with mAb158 was also performed, and compared to IP-MS with the Aβ-selective antibody mAb1C3, where a monomeric Aβ1–16 peptide was added to the protofibril preparation. Aβ1–16 is known for its poor aggregation propensity, and acted therefore as a selectivity marker. The results obtained confirmed the protofibril conformation selectivity of mAb158.


Related Articles

  • Diversity of Senile Plaques in Alzheimer's Disease as Revealed by a New Monoclonal Antibody that Recognizes an Internal Sequence of the A� Peptide. R�bano, Alberto; Jim�nez-Huete, Adolfo; Acevedo, Boris; Calero, Miguel; Ghiso, Jorge; Vald�s, Israel; Gavilondo, Jorge; Frangione, Blas; M�ndez, Enrique // Current Alzheimer Research;Oct2005, Vol. 2 Issue 4, p409 

    In order to have more specific tools available to approach amyloidogenesis in Alzheimer's disease (AD), we have produced several polyclonal and monoclonal antibodies that recognize specific sequences of the amyloid � (A�) peptide. Here we present results that demonstrate that our...

  • Quantitative analysis of amyloid-� peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Gelfanova, Valentina; Higgs, Richard E.; Dean, Robert A.; Holtzman, David M.; Farlow, Martin R.; Siemers, Eric R.; Boodhoo, Amechand; Yue-Wei Qian; Xiaohua He; Zhaoyan Jin; Fisher, Deborah L.; Cox, Karen L.; Hale, John E. // Briefings in Functional Genomics & Proteomics;Jun2007, Vol. 6 Issue 2, p149 

    Immunoprecipitation (IP) combined with matrix-assisted laser desorption ionization (MALDI) time of flight (Tof) mass spectrometry has been used to develop quantitative assays for amyloid-� (A�) peptides in cerebrospinal fluid (CSF). Inclusion of ISN labelled standard peptides allows...

  • Clearance of Amyloid-β Peptide by Neuronal and Non-Neuronal Cells: Proteolytic Degradation by Secreted and Membrane associated Proteases. Panchal, Maï; Lazar, Noureddine; Munoz, Noeli; Fahy, Christine; Clamagirand, Christine; Brouard, Jean-Paul; Dubost, Lionel; Cohen, Paul; Brakch, Noureddine; Rholam, Mohamed // Current Neurovascular Research;Oct2007, Vol. 4 Issue 4, p240 

    Deposition of amyloid-β peptide (Aβ) in the brain is an early and invariant feature of all forms of Alzheimer's disease (AD). As for all proteins or peptides, the steady-state level of Aβ peptide is determined not only by its production, but also by its degradation. So, overactive...

  • Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease Inhibitor. Costa, Rita; Ferreira-da-Silva, Frederico; Saraiva, Maria J.; Cardoso, Isabel // PLoS ONE;2008, Vol. 3 Issue 8, p1 

    Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of amyloid β-peptide (A-Beta) in the brain. Transthyretin (TTR) is a tetrameric protein of about 55 kDa mainly produced in the liver and choroid plexus of the brain. The known physiological functions of...

  • ESI-MS identification of the minimal zinc-binding center in natural isoforms of β-amyloid domain 1-16. Popov, I.; Indeikina, M.; Kononikhin, A.; Starodubtseva, N.; Kozin, S.; Makarov, A.; Nikolaev, E. // Molecular Biology;May2013, Vol. 47 Issue 3, p440 

    Alzheimer's disease is a lethal neurodegenerative pathology accompanied by the formation of water-soluble neurotoxic oligomers of the human β-amyloid peptide, Aβ, which are then accumulated as polymeric extracellular aggregates (the so-called amyloid plaques). The human Aβ isoform...

  • SDS-PAGE analysis of Aβ oligomers is disserving research into Alzheimer's disease: appealing for ESI-IM-MS. Pujol-Pina, Rosa; Vilaprinyó-Pascual, Sílvia; Mazzucato, Roberta; Arcella, Annalisa; Vilaseca, Marta; Orozco, Modesto; Carulla, Natàlia // Scientific Reports;10/9/2015, p1 

    The characterization of amyloid-beta peptide (Aβ) oligomer forms and structures is crucial to the advancement in the field of Alzheimer´s disease (AD). Here we report a critical evaluation of two methods used for this purpose, namely sodium dodecyl sulfate polyacrylamide gel...

  • Findings could spoil current approaches to an Alzheimer's cure.  // Long-Term Living: For the Continuing Care Professional;Apr2010, Vol. 59 Issue 4, p12 

    The article focuses on the recent study in "Biological Psychiatry" which states that amyloid beta protein that is consider one of the hallmarks of Alzheimer's disease patients is also present among healthy elderly people.

  • Neurodegenerative disease: Putting the brakes on cognitive decline. Smith, Adam // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p507 

    Reports on a study appearing in the May 22, 2003 issue of 'Neuron,' which suggests that antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Immunoreactivity of human sera for aggregated beta-amyloid plaques; Generation of antibodies against aggregated beta-amyloid...

  • Amyloid-β vaccine for Alzheimer disease. Novak, Kristine // Nature Medicine;Aug99, Vol. 5 Issue 8, p870 

    Discusses the use of amyloid-beta peptide vaccine for the treatment of Alzheimer's disease (AD). Reversal of amyloid-beta plaque formation; Reduction in the behavioral and neurophysiological symptoms of AD.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics